Automated summaries of serious adverse events in the hepatitis C antiviral long-term treatment against cirrhosis trial

被引:2
|
作者
Bell, Margaret C. [1 ]
Robuck, Patricia R. [2 ]
Wright, Elizabeth C. [3 ]
Mihova, Marina S. [1 ]
Hofmann, Charlotte [4 ]
De Santo, Jennifer L. [5 ]
Milstein, Susan L. [6 ]
Richtmyer, Pamela A. [1 ,7 ]
Shelton, Janel L. [8 ]
Cormier, Maureen [9 ]
King, Debra L. [10 ]
Park, Choon J. [11 ]
Molchen, Wallis A. [12 ]
Park, Yoon [13 ]
Kelley, Michelle [14 ]
机构
[1] New England Res Inst, Watertown, MA 02472 USA
[2] NIDDKD, Div Digest Dis & Nutr, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA
[3] NIDDKD, Off Director, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA
[4] Virginia Commonwealth Univ, Med Ctr, Hepatol Sect, Richmond, VA USA
[5] Univ Colorado Denver, Div Gastroenterol & Hepatol, Aurora, CO USA
[6] Univ So Calif, Hepatitis Res & Treatment Ctr, Los Angeles, CA USA
[7] Univ Michigan, Dept Internal Med, Div Gastroenterol, Ann Arbor, MI 48109 USA
[8] Univ Texas SW Med Ctr Dallas, Div Digest & Liver Dis, Dallas, TX 75390 USA
[9] Univ Massachusetts, Sch Med, Dept Med, Worcester, MA USA
[10] St Louis Univ, Sch Med, Div Gastroenterol & Hepatol, St Louis, MO USA
[11] Univ Calif Irvine, Dept Med, Irvine, CA 92717 USA
[12] Massachusetts Gen Hosp, Gastrointestinal Unit, Med Serv, Boston, MA 02114 USA
[13] NIDDKD, Liver Dis Branch, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA
[14] Univ Connecticut Hlth Care, Gen Clin Res Ctr, Farmington, CT USA
基金
美国国家卫生研究院;
关键词
EVOLUTION;
D O I
10.1177/1740774509348525
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background Even though adverse event (AE) collection and official accounting are mandatory for clinical trials, there are limited detailed guidelines specifying how to summarize the event for reporting in a timely and expeditious manner. This article details the AE and serious adverse event (SAE) reporting summary developed for a large multi-center National Institutes of Health (NIH)-sponsored clinical trial. Purpose To review and analyze the large volume of AE data reported by 10 sites (806 SAEs and 19,034 AEs from August 2000 to May 2007) the automated SAE summary was developed. It was designed to ensure timeliness and clarity in the complex process of AE review and reporting. Methods The AE and SAE case report forms (CRFs) as well as the automated SAE summary were developed within a database management system developed by the Data Coordinating Center (DCC) which allowed for web-based data entry at the DCC and 10 sites and offered immediate overall and site-specific reports accessible by the DCC, site, and NIH project staff. Results The automated SAE summary pulled data from multiple CRFs to create a succinct and informative summary and allowed for prompt and easy reporting to the regulatory agencies. The summary was adaptable to the needs of reviewers because of the availability of multiple search options.
引用
收藏
页码:618 / 627
页数:10
相关论文
共 50 条
  • [41] Antiviral Treatment of Recurrent Hepatitis C After Liver Transplantation: Predictors of Response and Long-Term Outcome
    Selzner, Nazia
    Renner, Eberhard L.
    Selzner, Markus
    Adeyi, Oyedele
    Kashfi, Arash
    Therapondos, George
    Girgrah, Nigel
    Herath, Chaturika
    Levy, Gary A.
    Lilly, Leslie
    TRANSPLANTATION, 2009, 88 (10) : 1214 - 1221
  • [42] Long-Term Impact of Antiviral Therapy in the Natural History of Chronic Hepatitis C
    Cordero-Ruiz, Patricia
    Carmona-Soria, Isabel
    Caunedo-Alvarez, Angel
    Herrerias, Juan M.
    Vilches-Arenas, Angel
    GASTROENTEROLOGY, 2014, 146 (05) : S256 - S256
  • [43] Long-term prospective study of antiviral therapy on reduced development of hepatocellular carcinoma in chronic Hepatitis C patients with cirrhosis.
    Shiratori, Y
    Ito, Y
    Yokosuka, O
    Imazeki, F
    Nakata, R
    Tanaka, N
    Arakawa, Y
    Katamoto, T
    Unuma, T
    Hirota, K
    Takano, S
    Hirano, M
    Kawase, T
    Hashimoto, E
    Yoshida, H
    Ohashi, Y
    Omata, M
    HEPATOLOGY, 2002, 36 (04) : 356A - 356A
  • [44] DOES ANTIVIRAL TREATMENT AFFECT THE CLINICAL LONG-TERM OUTCOME OF HEPATITIS DELTA?
    Wranke, A.
    Serrano, B. C.
    Heidrich, B.
    Kirschner, J.
    Bremer, B.
    Hardtke, S.
    Deterding, K.
    Port, K.
    Cornberg, M.
    Manns, M. P.
    Wedemeyer, H.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S163 - S164
  • [45] Factors predicting outcomes of hepatitis B-related cirrhosis patients with long-term antiviral therapy
    Jin, Xiaoli
    Li, Xiaofei
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2021, 120 (02) : 914 - 914
  • [46] Factors predicting outcomes of hepatitis B-related cirrhosis patients with long-term antiviral therapy
    Lin, Chih-Lin
    Tseng, Kuo-Chih
    Chen, Kuan-Yang
    Liao, Li-Ying
    Kao, Jia-Horng
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2020, 119 (10) : 1483 - 1489
  • [47] Long-term Evolution of Estimated Glomerular Filtration Rate in Patients With Antiviral Treatment for Hepatitis C Virus Infection
    Liu, Chen-Hua
    Lin, Jou-Wei
    Liu, Chun-Jen
    Su, Tung-Hung
    Wu, Jo-Hsuan
    Tseng, Tai-Chung
    Chen, Pei-Jer
    Kao, Jia-Horng
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2023, 21 (02) : 424 - +
  • [48] ADVERSE CHILDHOOD EVENTS (ACES) AND LONG-TERM BREAST CANCER TREATMENT SEQUALAE
    Ranallo, Lori
    He, Jianghua
    Van Goethem, Karla
    Denes-Collar, Karin
    Myers, Jamie
    ONCOLOGY NURSING FORUM, 2024, 51 (02)
  • [49] Local adverse events associated with long-term treatment by implantable insulin pumps
    Belicar, P
    Lassmann-VAgue, V
    DIABETES CARE, 1998, 21 (02) : 325 - 326
  • [50] Long-term treatment with ramipril after invasive revascularization reduces serious cardiac events
    Kjoller-Hansen, L
    Steffensen, R
    Grande, P
    CORONARY ARTERY DISEASE: PREVENTION TO INTERVENTION, 2000, : 669 - 674